Cellumen Spins Off Personalized Medicine Company | GenomeWeb
NEW YORK (GenomeWeb News) – Cellumen said yesterday that it has spun off its personalized medicine unit, called Cernostics Pathology.
 
Pittsburgh-based Cellumen said that Cernostics will provide digital imaging pathology and tissue-based diagnostics products and services for personalized medicine applications. It added that the spinout would build on Cellumen’s current collaborations with partners, such as the Mayo Clinic and Foundation, in developing a breast cancer diagnostic and theranostic test.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.